心臟衰竭药物市场－全球产业规模、份额、趋势、机会及预测（依药物类别、通路、地区及竞争格局划分，2021-2031年）

全球心臟衰竭药物市场预计将从 2025 年的 84.7 亿美元成长到 2031 年的 122.8 亿美元，年复合成长率为 6.39%。

此类别涵盖多种药物，例如利尿剂和血管收缩素转化酵素抑制剂，旨在提高心臟效率并缓解临床症状。推动这一增长的关键因素是全球人口快速老化以及高血压和糖尿病等合併症盛行率的不断上升，这两者都会增加心臟衰竭的风险。日益加重的疾病负担推动了对先进治疗方法的巨大需求，并促进了新型药物疗法的持续研发。例如，美国心臟衰竭协会 (HFSA) 估计，到 2024 年，美国将有约 670 万成年人患有心臟衰竭。

新兴药物和先进治疗方法的高昂成本是市场扩张的一大障碍。在许多开发中国家，有限的医疗报销预算限制了患者获得这些昂贵药物的机会，往往迫使医疗服务提供者依赖价格较低的学名药来治疗患者。因此，这些资金限制了创新型心臟衰竭治疗药物生产商的商机，并减缓了全球市场的整体发展。

市场驱动因素

全球心臟衰竭盛行率不断上升以及人口快速老化是市场扩张的关键驱动因素。预期寿命延长增加了心臟衰竭的累积风险，从而形成了一个需要长期管理的庞大患者群体。文明病相关合併症的增加进一步加剧了这种人口结构变化，加速了疾病进展，并增加了对医疗干预的需求。根据美国心臟衰竭协会2024年9月发布的报告《2024年心臟衰竭统计：心臟衰竭流行病学和预后统计》，预计到2050年，美国成年心臟衰竭患者人数将达到1140万，这一激增与对有效治疗性介入日益增长的迫切需求直接相关。

同时，新型药物治疗方法和药物类别的进步正在从根本上改变治疗模式。血管收缩素受体/脑啡肽酶抑制剂和钠-葡萄糖共同输送体2抑制剂等创新药物的引入，与传统治疗方法相比，带来了更优的临床疗效，从而促进了其在临床上的广泛应用。製药公司正利用这些科学突破，将高价值疗法商业化，以占据可观的市场份额。例如，诺华在2023年度报告（2024年1月发布）中披露，其心臟衰竭治疗药物Entresto的销售额增长了30%，达到60亿美元。同时，勃林格殷格翰在其2023年度报告（2024年4月发布）中披露，其药物Jardiance的销售额达到74亿欧元，这充分展现了这些现代治疗领域巨大的商业性影响力。

市场挑战

新兴药物和先进治疗方法带来的巨额经济成本是全球心臟衰竭治疗市场的主要阻碍因素。创新药物往往定价高昂，超越公共医疗预算和报销体系的负担能力，尤其是在开发中国家。当医疗体系面临如此严峻的财政困境时，医疗服务提供者往往被迫优先选择价格较低的学名药，而非新药。这种趋势直接限制了新型治疗方法生产商的收入潜力，并减缓了临床先进治疗方法的商业性化应用。

此外，医疗基础设施面临的经济负担也阻碍了高成本药物的广泛应用。根据美国心臟协会预测，截至2024年，到2050年，美国心血管疾病的总成本预计将达到1.8兆美元。如此巨大的支出预测迫使支付方采取严格的成本控制措施。因此，由于报销限制阻碍了患者获得有效但昂贵的心臟衰竭治疗方案，市场面临持续的压力。

市场趋势

GLP-1促效剂在肥胖相关心臟衰竭治疗中的应用，显着改变了治疗格局，使治疗重点转向那些会加重心臟衰竭的代谢併发症。这一趋势标誌着治疗策略从传统的血流动力学管理转向针对疾病系统性病因的治疗方法，尤其适用于射血分数保留且BMI较高的患者。製药公司正有效地利用这些药物，降低越来越多患者群体的心血管风险，使其不再局限于简单的体重管理，而是转向临床心血管保护。例如，在2024年3月发布的新闻稿中，诺和诺德宣布，在关键性SELECT试验中，与安慰剂相比，2.4毫克Semaglutide可使主要心血管不利事件的风险降低20%，该试验涉及FDA核准Wegovy上市。

此外，基因治疗和再生医学研发管线的兴起，致力于为基因明确的心肌病提供根治性干预措施，将重点从症状管理转向解决潜在的分子病因。这种创新方法正透过病毒载体递送系统的进步而获得广泛应用，这些系统旨在恢復心臟组织中的功能性蛋白质表现。该领域的临床试验已产生数据，支持长期结构改善和疾病逆转的潜力。值得注意的是，2024年11月，Rocket Pharmaceuticals公司报告称，其用于治疗达农病的在临床实验基因疗法在12个月时使左心室质量指数中位数降低了24%；该结果发表于《新英格兰医学杂誌》。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球心臟衰竭药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类别（ACE抑制剂、血管收缩素II受体阻断剂、 β阻断剂、利尿剂、醛固酮拮抗剂、强心药、其他）
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美心臟衰竭药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲心臟衰竭药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区心臟衰竭药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲心臟衰竭药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲心臟衰竭药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球心臟衰竭药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bayer AG
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Co
• Amgen Inc
• Boehringer Ingelheim GmbH
• Pfizer Inc
• Johnson & Johnson
• Eli Lilly and Company

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Heart Failure Therapeutics Market is projected to expand from USD 8.47 Billion in 2025 to USD 12.28 Billion by 2031, reflecting a compound annual growth rate of 6.39%. This sector encompasses a wide variety of pharmaceutical agents, such as diuretics and angiotensin-converting enzyme inhibitors, which are designed to enhance cardiac efficiency and mitigate clinical symptoms. The primary catalysts driving this growth are the rapidly aging global population and the rising prevalence of comorbidities like hypertension and diabetes, both of which predispose individuals to cardiac insufficiency. This increasing disease burden generates substantial demand for advanced treatment options and fuels the continuous creation of novel pharmacotherapies; for instance, the Heart Failure Society of America estimated that approximately 6.7 million adults in the United States were living with heart failure in 2024.

A significant barrier hindering the market's expansion is the high financial cost associated with emerging drug classes and advanced therapeutic regimens. In many developing nations, limited healthcare reimbursement budgets restrict patient access to these premium medications, often compelling healthcare providers to rely on older, lower-cost generic alternatives for patient care. Consequently, these economic constraints limit revenue opportunities for manufacturers of innovative heart failure drugs and slow the overall progression of the global market.

Market Driver

The escalating global prevalence of heart failure combined with a rapidly aging geriatric population acts as the primary engine for market expansion. As life expectancy rises, the cumulative risk of developing cardiac insufficiency increases, establishing a sustained patient base that requires long-term management. This demographic shift is further intensified by the growing incidence of lifestyle-related comorbidities, which accelerates disease progression and heightens the need for medical intervention. According to the Heart Failure Society of America's September 2024 report, 'HF Stats 2024: Heart Failure Epidemiology and Outcomes Statistics,' the number of adults living with heart failure in the United States is expected to reach 11.4 million by 2050, a surge that directly correlates with an increased urgency for effective therapeutic interventions.

Simultaneously, advancements in novel pharmacological therapies and drug classes are fundamentally reshaping the treatment landscape. The introduction of innovative agents, such as Angiotensin Receptor-Neprilysin Inhibitors and Sodium-Glucose Cotransporter-2 inhibitors, provides superior clinical outcomes compared to traditional regimens, thereby driving widespread clinical adoption. Pharmaceutical companies are capitalizing on these scientific breakthroughs by commercializing high-value therapeutics that capture significant market share. For example, Novartis reported in its 'Annual Report 2023' (January 2024) that sales of the heart failure drug Entresto increased by 30% to USD 6.0 billion, while Boehringer Ingelheim's 'Annual Report 2023' (April 2024) noted that sales of Jardiance reached EUR 7.4 billion, illustrating the commercial impact of these modern therapeutic classes.

Market Challenge

The substantial financial cost associated with emerging drug classes and advanced therapeutic regimens represents a primary restraint on the global heart failure therapeutics market. Innovative pharmaceutical agents often come with premium pricing that exceeds the capacity of public health budgets and insurance reimbursement plans, especially in developing nations. When healthcare systems encounter these strict financial limitations, providers are frequently forced to prioritize older, lower-cost generic alternatives over newer, patented medications. This trend directly restricts the revenue potential for manufacturers of novel therapies and decelerates the commercial adoption of clinically advanced treatments.

Furthermore, the economic burden placed on healthcare infrastructure creates a barrier to the widespread entry of high-cost drugs. According to the American Heart Association, the total cost of cardiovascular disease in the United States was projected in 2024 to potentially reach $1.8 trillion by 2050. This magnitude of projected expenditure forces payers to implement rigorous cost-containment measures. Consequently, the market faces sustained pressure as restricted reimbursement policies hamper the ability of patients to access effective but expensive heart failure management solutions.

Market Trends

The adoption of GLP-1 agonists for obesity-related heart failure is significantly altering the treatment landscape by targeting metabolic comorbidities that exacerbate cardiac insufficiency. This trend marks a departure from traditional hemodynamic modulation toward therapies that address systemic drivers of disease, particularly in patients with preserved ejection fraction and a high body mass index. Pharmaceutical developers are successfully leveraging these agents to mitigate cardiovascular risks in this expanding patient demographic, moving beyond simple weight management to clinical cardiovascular protection. For instance, Novo Nordisk announced in a March 2024 press release regarding Wegovy's FDA approval that the pivotal SELECT trial demonstrated semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared to placebo.

Additionally, the emergence of gene therapy and regenerative medicine pipelines is focusing on delivering curative interventions for genetically defined cardiomyopathies, shifting the focus from symptom management to addressing root molecular causes. This innovative approach is gaining traction through the advancement of viral vector-based delivery systems designed to restore functional protein expression in cardiac tissue. Clinical trials in this sector are producing data that validates the potential for long-term structural improvement and disease reversal; notably, Rocket Pharmaceuticals reported in November 2024 that its investigational gene therapy for Danon disease resulted in a median 24% reduction in left ventricular mass index at 12 months, as published in the New England Journal of Medicine.

Key Market Players

• Bayer AG
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Co
• Amgen Inc
• Boehringer Ingelheim GmbH
• Pfizer Inc
• Johnson & Johnson
• Eli Lilly and Company

Report Scope

In this report, the Global Heart Failure Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Heart Failure Therapeutics Market, By Drug Class

• ACE Inhibitors
• Angiotensin 2 Receptor Blockers
• Beta Blockers
• Diuretics
• Aldosterone Antagonists
• Inotropes
• Others

Heart Failure Therapeutics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Heart Failure Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Heart Failure Therapeutics Market.

Available Customizations:

Global Heart Failure Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Heart Failure Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Heart Failure Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Heart Failure Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Heart Failure Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Heart Failure Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel

7. Europe Heart Failure Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Heart Failure Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. France Heart Failure Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Heart Failure Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Heart Failure Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Heart Failure Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Heart Failure Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Heart Failure Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Heart Failure Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Heart Failure Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Heart Failure Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Heart Failure Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Heart Failure Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Heart Failure Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. UAE Heart Failure Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. South Africa Heart Failure Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel

10. South America Heart Failure Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Heart Failure Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Colombia Heart Failure Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. Argentina Heart Failure Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Heart Failure Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Merck & Co., Inc.
• 15.4. AstraZeneca PLC
• 15.5. Bristol-Myers Squibb Co
• 15.6. Amgen Inc
• 15.7. Boehringer Ingelheim GmbH
• 15.8. Pfizer Inc
• 15.9. Johnson & Johnson
• 15.10. Eli Lilly and Company

16. Strategic Recommendations

17. About Us & Disclaimer